The interpretation and review of renal carcinoma, 2023 EMSO
10.3760/cma.j.cn112330-20231211-00182
- VernacularTitle:2023 ESMO肾癌精粹解读
- Author:
Xinan SHENG
1
;
Xieqiao YAN
;
Zhenhua LIU
;
Jun GUO
Author Information
1. 北京大学肿瘤医院泌尿肿瘤内科，北京 100142
- Keywords:
Renal carcinomas;
Research progress;
Clinical treatment decisions
- From:
Chinese Journal of Urology
2023;44(12):893-896
- CountryChina
- Language:Chinese
-
Abstract:
The 2023 European Society for Medical Oncology (ESMO) annual meeting reported on the research progress in the field of clinical treatment, biomarkers, and exploration of new drugs/mechanisms for renal carcinoma, which included the first phase III trial of vascular endothelial growth factor receptor-tyrosine kinase inhibitor/immune checkpoint inhibitor (VEGFR-TKI/ICI) combination in Chinese population, trials of hypoxia inducible factor-2α (hif-2α) inhibitor, programmed cell death-Ligand 1/cytotoxic T-lymphocyte-associated antigen 4 (PD-1/CTLA-4) bispecific monoclonal antibody and antibody-drug conjugate, biomarkers of peripheral blood, tissue glycan profiling and tissue protein. This article interprets and reviews important studies to help clinical treatment decisions.
